Background and importance  Mucopolysaccharidosis VII (MPSVII), also known as Sly syndrome, is an ultra-rare disease characterised by deficiency of β-glucuronidase. Sly phenotypes vary from severe forms with hydrops fetalis and skeletal dysplasia, hepatosplenomegaly, heart valve abnormalities and mental retardation, to milder forms with fewer manifestations.  

Aim and objectives  To compare the vancomycin pharmacokinetic (PK) profile observed in a newborn with MPSVII with that expected in an average neonate.

Material and methods  Clinical data were collected from the electronic medical record (Diraya), and an extensive literature research was made using different electronic databases (Pubmed, Scopus). Serum concentration–time profiles were adjusted to a one compartment neonatal population PK model incorporating body weight and renal function as the significant covariates, using the Abottbase PK System (PKS) programme.

Results  The patient was a 26-day-old male, with a postmenstrual age of 38 weeks, and diagnosed with MPS VII, who initially had phlebitis and fever during his stay in the neonatal intensive care unit. His blood cultures were positive for coagulase negative <i>Staphylococcus aureus</i>. The patient was treated with vancomycin 10 mg/kg/8 hours intravenously. PK were evaluated before the sixth dose, with weight of 2.2 kg, height 44 cm and a creatinine serum level of 0.92 mg/L. After obtaining a serum level of 123.6 μg/mL (normal trough range 10–15 μg/mL), vancomycin was stopped. After 2 days, serum levels were 11.4 μg/mL, so vancomycin was restarted at 10 mg/kg/12 hours. After four administrations, serum levels were again out of range (48.2 μg/mL), and the antimicrobial was switched to claxacillin. Based on the vancomycin levels, we estimated a half-life of 15.8 hours, instead of the 4–8 hours described daily dose represented the most common error (20.94%) in the CP examined. Consumption was calculated based on ex factory prices (VAT excluded), net of the temporary reductions provided for by law. Avoided costs were calculated based on inappropriate prescriptions and unauthorised treatments.

Results  4017 CR, 1267 patients (70.72% men; mean age 66.54 years) and 26 457.22 DDD (19.89 DDD/patient) were included in the study. The expenditure incurred was 1 214 876.87€. Data showed a significant decrease in the patient treated rate (–2%), DDD required (delta 2019–2017 = –9.33%) and expenditure incurred (delta 2019–17 = –52.65%). The consumption (DDD/pz) of levofloxacin did not increase during the study period (mean 11.22 DDD/pz), while a considerable increase was highlighted for ceftaroline, fosamil and micafungin. Systemic antifungal therapy was started empirically in 181 patients (68.5% men; mean age 65 years). Daptomycin was used for persistent methicillin resistant <i>Staphylococcus aureus</i> bacteraemia (delta 2019–2018 = +191.43). 3.68% of CR (148/4017) were deemed inappropriate. Drug costs were calculated based on costs saved were 29 730.37€. Pre- described daily dose represented the most common error (20.94%) in the CP examined.

Conclusion and relevance  Hospital pharmacists detected and prevented harmful errors in prescribing therapies. Supervision by hospital pharmacists can significantly improve the management of clinical risk, patient safety, optimisation of care and effective management of expenditure.

REFERENCES AND/OR ACKNOWLEDGEMENTS  

Conflict of interest  No conflict of interest

Background and importance  Misuse and abuse of antibiotics are among the main causes of the increase in antibiotic resistance. Monitoring and evaluation of antibiotic prescriptions is an important activity involving the hospital pharmacist.

Aim and objectives  The aim of the study was to assess attitudes and practices towards antibiotics. The objectives were to assess clinical governance, prescriptive appropriateness as well as costs incurred.

Material and methods  A retrospective observational study was carried out from 1 January 2017 to 31 December 2019 in a university hospital. Outpatient dispensing was used for patient identification and data collection. Demographic, diagnostic, therapeutic and clinical variables were gathered. Consumption was expressed as defined daily dose (DDD). Drugs evaluated were: ticagycline, ceftazidime and beta-lactamase inhibitor, meropenem, ertapenem, ceftaroline, fosamil, cefotolozane and beta-lactamase inhibitor, levofloxacine, dalbavancine, linezolid, daptomycin, amphotericin B, voriconazole, caspofungin, micafungin and anidulafungin. First dispensation date was considered as the index date. Custom requests (CR) that reported prescribing errors were considered inappropriate. Drug costs were calculated based on costs incurred.
(cSSSI), and community acquired pneumonia (CAP). However, the most specific aspect of the drug is that it is a beta-lactam with activity against methicillin resistant *Staphylococcus aureus* (MRSA). These characteristics mean that a large part of its use in clinical practice is in off-label indications.

**Aim and objectives** To determine the use of ceftriaxone in the clinical practice of a third level hospital, and its effectiveness and safety.

**Material and methods** An observational retrospective study was conducted that included all patients treated with ceftriaxone in the hospital from May 2016 to September 2020. Variables studied were: age, sex, indication, dose, microorganism, clinical and microbiological cure, and adverse effects.

**Results** 57 patients received treatment with ceftriaxone, 75.4% men, with a median age of 69 years (28–89). In 11/57 patients it was used as empirical treatment (for suspected multiresistant germ) and in 46/57 as directed treatment, for the following indications: 13 bacteraemia, 14 endocarditis (with bacteremia), 15 pneumonia (11 with bacteremia, 1 with CNS infection and 2 with cSSSI), 2 cSSSI and 2 CNS infection. Infections were caused by MRSA in 23/46 patients, 15/46 by methicillin resistant coagulase negative *Staphylococcus*, 5/46 methicillin sensitive *Staphylococcus aureus* (MSAS), 2/46 *Streptococcus pneumoniae* and in 1 patient due to MSAS and *Streptococcus pneumoniae*. Methicillin resistant microorganisms caused the infections in 38/46 patients. The median duration of treatment was 7 days (1–42). Posology: 600 mg/8 hours was used in bacteremia, endocarditis and in CNS infection, and 600 mg/12 hours in cSSSI. The regimen used in pneumonia was 600 mg/12 hours in 6/15 patients and 600 mg/8 hours in 9/15 patients (8 of whom had bacteremia and one had concomitant CNS infection). The dosage used in the empirical treatment was 600 mg/12 hours in eight patients and 600 mg/8 hours in three. In six patients it was adjusted for renal function. 78.7% of the patients presented with clinical resolution (82.9% microbiological). Thrombopenia was detected in two patients, probably associated with treatment with the drug.

**Conclusion and relevance** Our results suggested that ceftriaxone was effective in severe cases of methicillin resistant gram positive infections. In most cases, ceftriaxone was used for off-label indications. In these cases, higher dosages are being recommended, which are usually prolonged in time, so it is advisable to evaluate the profile of adverse effects.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Conflict of interest No conflict of interest

**4CPS-256**

HEPATITIS C RETREATMENT OF A PATIENT WHO FAILED MULTIPLE TREATMENTS INCLUDING PROTEASE INHIBITOR AND NON-STRUCTURAL PROTEIN 5A INHIBITORS: A CASE REPORT

JM Sotoca*, M Rodriguez-Reyes, Hospital Clinic Barcelona, Pharmacy Service, Barcelona, Spain

10.1136/ejhpharm-2021-eahpconf.88

Background and importance It is well documented that direct acting antiviral (DAA) combinations in the treatment of hepatitis C virus (HCV) achieve high rates of sustained virologic response. However, studies on retreatment options for patients who have failed several DAA treatment regimens that include non-structural protein 5A (NS5A) inhibitors remain scarce.

**Aim and objectives** To assess the efficacy of glecaprevir/pibrentasvir plus sofosbuvir and ribavirin for 12 weeks in genotype 1b patient with compensated cirrhosis who had virologic failure to multiple treatments including regimens containing NS5A inhibitors.

**Material and methods** A 50-year-old man failed multiple hepatitis C treatments, including peginterferon plus ribavirin (2003) for 9 months, sofosbuvir/ledipasvir plus ribavirin (2014) for 24 weeks, sofosbuvir/glecaprevir plus ribavirin (2015) for 24 weeks and sofosbuvir/velpatasvir plus ribavirin (2018) for 24 weeks. Adherence to these treatments was correct according to the dispensing records. Headache, fatigue, anaemia, nausea and pruritus were reported with oral treatments, but drug withdrawal was not required. However, peginterferon was stopped due to anxiety and depression.

There are no specific algorithms to guide retreatment decisions. These must be guided by the drugs administered in previous treatment courses or, if resistance testing is performed, by probabilities of response according to the resistance profile and the treating team’s experience. Resistance testing showed resistance to NS5A inhibitors: daclatasvir, elvastavir, ledipasvir, ombitasvir and velpatasvir, but not to pibrentasvir. The multidisciplinary team decided on a new treatment with glecaprevir/pibrentasvir plus sofosbuvir and ribavirin for 12 weeks and it was started in November 2019. Prior to treatment, drug interactions were checked. An undetectable HCV RNA level 12 weeks after completion of therapy (SVR12) defined treatment success.

**Results** Two potential drug interactions were detected: (1) gemfibrozil was discontinued because of the increased risk of gastrointestinal side effects; (2) due to the potential increase in carvedilol concentrations, close monitoring of heart rate and blood pressure was recommended. The patient achieved SVR12 with the fifth hepatitis C treatment with glecaprevir/pibrentasvir plus sofosbuvir and ribavirin for 12 weeks and it was started in November 2019. Prior to treatment, drug interactions were checked. An undetectable HCV RNA level 12 weeks after completion of therapy (SVR12) defined treatment success.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Conflict of interest No conflict of interest

**4CPS-257**

RELEVANCE OF RITONAVIR INTERACTIONS IN HIV TREATMENTS THAT INVOLVE TREATMENT MODIFICATION


10.1136/ejhpharm-2021-eahpconf.89

Background and importance The protease inhibitor (PI)/enhancer combination, more than 20 years after its appearance, continues to be the antiretroviral therapy (ART) of choice in certain circumstances due to its high genetic barrier. Ritonavir (RTV) acts as an enhancer and has a higher potential for drug interactions.